🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

16 recruiting trials

for Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide Observational Study Protocol: LIVER-R NCT06252753n/a160 sites📍 Birmingham📍 Mobile📍 Phoenix AstraZeneca · Tests: Durvalumab-based combination therapies in observational study setting, Durvalumab-based combination therapies in observ… A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma NCT05440708Phase 1, Phase 221 sites📍 Birmingham📍 La Jolla📍 Los Angeles Tvardi Therapeutics, Incorporated · Tests: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression NCT07327034Phase 251 sites📍 Hefei📍 Hefei📍 Hefei Abbisko Therapeutics Co, Ltd · Tests: ABSK-011+BSC, Placebo+BSC Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483Phase 1122 sites📍 Phoenix📍 Tucson📍 Palo Alto Exelixis · Tests: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy NCT07493668Phase 21 site📍 Seongnam-si CHA University · Tests: Fostrox, Lenvatinib Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. NCT07227012Phase 1, Phase 260 sites📍 Irvine📍 Irvine📍 Irvine Pfizer · Tests: PF-08634404, Ipilimumab Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598Phase 212 sites📍 Beverly Hills📍 La Jolla📍 Miami Replimune, Inc. · Tests: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma NCT06737913Phase 23 sites📍 Lanzhou📍 Guangzhou📍 Zhengzhou Sun Yat-sen University · Tests: HAI Adebrelimab, intravenous infusion (IV) of Adebrelimab (ADE), intravenous infusion (IV) of Bevacizumab (Bev.), HAIC … Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer NCT05168163Phase 216 sites📍 Scottsdale📍 Jacksonville📍 Weston Academic and Community Cancer Research United · Tests: Atezolizumab, Cabozantinib, Lenvatinib Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors NCT05269381Phase 1, Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma NCT07793695Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care target… A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma NCT07010497Phase 23 sites📍 Seoul📍 Seoul📍 Seoul Asan Medical Center · Tests: irpagratinib MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. NCT07607769n/a24 sites📍 Ancona📍 Ancona📍 Bergamo AstraZeneca · Tests: STRIDE A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC NCT07547553Phase 1, Phase 221 sites📍 Bengbu📍 Hefei📍 Hefei Huahui Health · Tests: Will receive HH-009 injection 20 mg/kg, Q3W, Will receive HH-009 injection 30 mg/kg, Q3W A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) NCT07291076Phase 1, Phase 267 sites📍 Duarte📍 Los Angeles📍 Chicago Bristol-Myers Squibb · Tests: Pumitamig, Ipilimumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy